

Clinical Policy: Valganciclovir (Valcyte)

Reference Number: ERX.NPA.33

Effective Date: 07.01.15

Last Review Date: 02.22

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

Description

Valganciclovir (Valcyte[®]) is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor.

FDA Approved Indication(s)

Valcyte is indicated for:

- Adult patients
 - Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)
 - Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-])
- Pediatric patents
 - Prevention of CMV disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions[™] that Valcyte is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. CMV Prophylaxis in Heart, Kidney, or Kidney-Pancreas Transplant (must meet all):

1. Member has a history of heart, kidney, or kidney-pancreas transplant;
2. Organ donor or recipient is CMV seropositive;
3. Dose does not exceed 900 mg per day.

Approval duration:

Heart or kidney-pancreas transplant – 6 months

Kidney transplant – 200 days

B. CMV Retinitis (must meet all):

1. Diagnosis of CMV retinitis;
2. Prescribed by or in consultation with an ophthalmologist;
3. Age > 16 years;
4. Member is human immunodeficiency virus (HIV)-positive;
5. Dose does not exceed the following:
 - a. Induction: 1,800 mg per day for 21 days;
 - b. Maintenance: 900 mg per day.

Approval duration: 4 months

C. CMV Prophylaxis in Liver or Lung Transplant (off-label) (must meet all):

1. Member has a history of liver or lung transplant;
2. Organ donor or recipient is CMV seropositive;

3. Dose does not exceed 900 mg per day.

Approval duration:

Liver transplant – 6 months

Lung transplant – 12 months

D. CMV-Associated Gastrointestinal Diseases (off-label) (must meet all):

1. Diagnosis of a CMV-associated gastrointestinal disease (e.g., CMV esophagitis, colitis);
2. Prescribed by or in consultation with an infectious disease specialist or gastroenterologist;
3. Age > 16 years;
4. Member is HIV-positive;
5. Dose does not exceed 1,800 mg per day.

Approval duration: 42 days

E. Post-Transplant CMV Infection (off-label) (must meet all):

1. Diagnosis of CMV infection following hematopoietic stem cell transplant or solid organ transplant (e.g., kidney, lung, heart, liver, pancreas, intestine);
2. Dose does not exceed 1,800 mg per day.

Approval duration: 14 days

F. Other diagnoses/indications

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. CMV Prophylaxis in Heart, Kidney, or Kidney-Pancreas Transplant (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. Member meets one of the following (a or b):
 - a. Heart or kidney-pancreas transplant: Member has not received ≥ 6 months of therapy;
 - b. Kidney transplant: Member has not received ≥ 200 days of therapy;
3. If request is for a dose increase, new dose does not exceed 900 mg per day.

Approval duration:

Heart or kidney-pancreas transplant – Up to 6 months total

Kidney – Up to 200 days total

B. CMV Retinitis (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. Adherent to antiretroviral therapy (ART) as evidenced by pharmacy claims history;
3. If member has received ≥ 4 months of therapy, member meets one of the following (a or b):
 - a. CD4 count is < 100 cells/mm³ (within the last 3 months);
 - b. Continuation of therapy is recommended by an ophthalmologist;
4. If request is for a dose increase, new dose does not exceed 900 mg per day.

Approval duration: 3 months

C. CMV Prophylaxis in Liver or Lung Transplant (off-label) (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. Member meets one of the following (a or b):
 - a. Liver transplant: Member has not received ≥ 6 months of therapy;
 - b. Lung transplant: Member has not received ≥ 12 months of therapy;
3. If request is for a dose increase, new dose does not exceed 900 mg per day.

Approval duration:

Liver transplant – Up to 6 months total

Lung transplant – Up to 12 months total

D. CMV-Associated Gastrointestinal Diseases (off-label) (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. Adherent to ART as evidenced by pharmacy claims history;
3. Member has experienced disease relapse since initial request;
4. If request is for a dose increase, new dose does not exceed 900 mg per day.

Approval duration: Duration of request or 3 months (whichever is less)

E. Post-Transplant CMV Infection (off-label) (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. Member continues to have clinical symptoms and a virologic clearance above a threshold negative value based on laboratory monitoring with CMV quantitative nucleic acid testing (QNAT) or pp65 antigenemia once a week;
3. If request is for a dose increase, new dose does not exceed 1,800 mg per day.

Approval duration: Duration of request or 3 months (whichever is less)

F. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.

Approval duration: Duration of request or 12 months (whichever is less); or

2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

AIDS: acquired immunodeficiency syndrome
ART: antiretroviral therapy
BSA: body surface area
CMV: cytomegalovirus

CrCl: creatinine clearance
FDA: Food and Drug Administration
HIV: human immunodeficiency virus
QNAT: quantitative nucleic acid testing

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): hypersensitivity
- Boxed warning(s): hematologic toxicity, impairment of fertility, fetal toxicity, mutagenesis, and carcinogenesis

Appendix D: General Information

- Based on the 2019 American Society of Transplantation and the 2018 Third International Consensus guidelines for CMV management in solid organ transplantation:
 - 3 to 6 months of prophylaxis therapy is recommended for donor+/recipient- and recipient+ heart transplant, kidney/pancreas transplant, and liver transplant recipients.
 - 6 to 12 months of prophylaxis therapy is recommended for donor+/recipient- and recipient+ lung transplant recipients.
 - CMV disease should be treated with either IV ganciclovir (for severe, life-threatening disease or mild-to-moderate disease) or PO Valcyte (for mild-to-moderate disease). Patients should be treated for a minimum of 2 weeks and until clinical symptoms have resolved and virologic

- clearance is below a threshold negative value based on weekly laboratory monitoring with CMV QNAT or pp65 antigenemia. After completion of full-dose antiviral treatment, secondary prophylaxis intended to prevent CMV relapse is not recommended as a routine practice.
- Based on the results of the IMPACT study, Valcyte prophylaxis for 200 days in kidney transplant patients resulted in a reduction in CMV disease. At 2 years post-transplant, CMV disease occurred in significantly less patients in the 200- vs. the 100-day group: 21.3% vs. 38.7%, respectively ($p < 0.001$).
 - Although Valcyte is not FDA approved for the prevention of CMV disease in liver transplant patients, consensus treatment guidelines support the use of Valcyte in this transplant type. The FDA has cautioned against valganciclovir prophylaxis in liver recipients due to high rate of tissue-invasive disease compared to oral ganciclovir.
 - Data supporting the use of Valcyte for lung transplant patients come from Finlen et al, who concluded that 12 months of Valcyte prophylaxis compared with 3 months provided a protective benefit with a CMV incidence of 12% vs 55% respectively (HR 0.13, CI: 0.03-0.61, $p = 0.009$). In another randomized clinical trial by Palmer et al, extending the duration of Valcyte prophylaxis from 3 months to 12 months decreased the incidence of CMV disease from 64% to 10% ($p < 0.001$).
 - Per CDC guidelines for the treatment of CMV retinitis, Valcyte may be used in combination with ganciclovir intraocular implant for patients with immediate sight-threatening lesions (adjacent to the optic nerve or fovea).
 - Chronic maintenance therapy is not routinely recommended for CMV gastrointestinal disease, unless there is concurrent retinitis or relapses have occurred.
 - The safety and efficacy of Valcyte for oral solution and tablets have not been established in children for prevention of CMV disease in pediatric liver transplant patients, in kidney transplant patients less than 4 months of age, in heart transplant patients less than 1 month of age, in pediatric AIDS patients with CMV retinitis, and in infants with congenital CMV infection. In 2010, the FDA added an upper limit to pediatric dosing calculation to prevent Valcyte overdosing in children with low body weight, surface area and below normal serum creatinine.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Adult Dosage		
Prevention of CMV disease in heart or kidney-pancreas transplant patients	900 mg (two 450 mg tablets) PO QD within 10 days of transplantation until 100 days post-transplantation	900 mg/day
Prevention of CMV disease in kidney transplant patients	900 mg (two 450 mg tablets) PO QD within 10 days of transplantation until 200 days post-transplantation	900 mg/day
Treatment of CMV retinitis	Induction: 900 mg (two 450 mg tablets) PO BID for 14-21 days Maintenance: 900 mg (two 450 mg tablets) PO QD	Induction: 1,800 mg/day; Maintenance: 900 mg/day
Prevention of CMV disease in liver transplantation [†]	900 mg (two 450 mg tablets) PO QD within 10 days of transplantation	900 mg/day
Prevention of CMV disease in lung transplantation [†]	900 mg (two 450 mg tablets) PO QD within 10 days of transplantation	900 mg/day
Treatment of CMV esophagitis [†] or colitis [†]	Induction: 900 mg (two 450 mg tablets) PO BID for 21-42 days Maintenance (may be considered in patients with relapse): 900 mg (two 450 mg tablets) PO QD	Induction: 1,800 mg/day; Maintenance: 900 mg/day
Treatment of post-transplant CMV infection [†]	900 mg PO BID for at least 14 days	1,800 mg/day

Indication	Dosing Regimen	Maximum Dose
Pediatric Dosage		
Prevention of CMV disease in kidney transplant patients 4 months to 16 years of age	Calculated dose in mg (7 x body surface area [BSA] x creatinine clearance [CrCl]*) PO QD within 10 days of transplantation until 200 days post-transplantation	900 mg/day
Prevention of CMV disease in heart transplant patients 1 month to 16 years of age	Calculated dose in mg (7 x BSA x CrCl*) PO QD within 10 days of transplantation until 100 days post-transplantation	900 mg/day
Treatment of post-transplant CMV infection†	Calculated dose in mg (7 x BSA x CrCl*) PO BID for at least 14 days	1,800 mg/day

*Calculated using a modified Schwartz formula

† Off-label indication

VI. Product Availability

- Oral solution: 50 mg/mL
- Tablet: 450 mg

VII. References

1. Valcyte Prescribing Information. South San Francisco, CA: Genentech USA, Inc.; November 2020. Available at <http://www.valcyte.com/> Accessed September 14, 2021.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2021. Available at: <http://www.clinicalpharmacology-ip.com>. Accessed September 14, 2021.
3. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: cytomegalovirus disease: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/cytomegalovirus-disease>. Last updated July 1, 2021. Last reviewed April 14, 2021. Accessed September 14, 2021.
4. Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. *Transplantation*. June 2018; 102 (6): 900-931.
5. Zamora MR, Davis RD, Leonard C. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. *Transplantation* 2005;80: 157–163.
6. Razonable RR, Humar A, and the AST Infectious Disease Community of Practice. Cytomegalovirus in solid organ transplantation. *Am J Transplant*. 2013 Mar;13 Suppl 4:93-106.
7. Marcelin JR, Beam E, Razonable RR. Cytomegalovirus infection in liver transplant recipients: Updates on clinical management. *World Journal of Gastroenterology : WJG*. 2014;20(31):10658-10667. doi:10.3748/wjg.v20.i31.10658.
8. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. *Clinical Transplantation*. 2019; 33: e13512.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
3Q 2018 annual review: no significant changes; references reviewed and updated.	04.25.18	08.18
1Q 2019 annual review: no significant changes, references reviewed and updated.	11.05.18	02.19
1Q 2020 annual review: no significant changes; references reviewed and updated.	12.02.19	02.20
1Q 2021 annual review: no significant changes; references reviewed and updated.	10.20.20	02.21

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2022 annual review: added off-label coverage for treatment of post-transplant CMV infection as supported by practice guidelines; references reviewed and updated.	12.02.21	02.22

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2015 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.